vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Palomar Holdings, Inc. (PLMR). Click either name above to swap in a different company.
Palomar Holdings, Inc. is the larger business by last-quarter revenue ($253.4M vs $247.1M, roughly 1.0× ANI PHARMACEUTICALS INC). On growth, Palomar Holdings, Inc. posted the faster year-over-year revenue change (62.7% vs 29.6%). Palomar Holdings, Inc. produced more free cash flow last quarter ($409.0M vs $29.1M). Over the past eight quarters, Palomar Holdings, Inc.'s revenue compounded faster (46.2% CAGR vs 34.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Palomar Holdings, Inc. is a specialty insurance holding company that primarily provides property insurance products for catastrophe-exposed residential and commercial assets. It mainly operates across the United States, focusing on core segments including earthquake, flood, and windstorm coverage to meet high-risk property protection demands of customers.
ANIP vs PLMR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $253.4M |
| Net Profit | $27.5M | — |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 28.7% |
| Net Margin | 11.1% | — |
| Revenue YoY | 29.6% | 62.7% |
| Net Profit YoY | 367.5% | — |
| EPS (diluted) | $1.14 | $2.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $253.4M | ||
| Q3 25 | $227.8M | $244.7M | ||
| Q2 25 | $211.4M | $203.3M | ||
| Q1 25 | $197.1M | $174.6M | ||
| Q4 24 | $190.6M | $155.8M | ||
| Q3 24 | $148.3M | $148.5M | ||
| Q2 24 | $138.0M | $131.1M | ||
| Q1 24 | $137.4M | $118.5M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $51.5M | ||
| Q2 25 | $8.5M | $46.5M | ||
| Q1 25 | $15.7M | $42.9M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $30.5M | ||
| Q2 24 | $-2.3M | $25.7M | ||
| Q1 24 | $18.2M | $26.4M |
| Q4 25 | 14.1% | 28.7% | ||
| Q3 25 | 15.9% | 27.4% | ||
| Q2 25 | 6.6% | 29.5% | ||
| Q1 25 | 13.3% | 30.8% | ||
| Q4 24 | -2.3% | 28.9% | ||
| Q3 24 | -13.8% | 25.9% | ||
| Q2 24 | 3.7% | 25.5% | ||
| Q1 24 | 14.8% | 29.0% |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | 21.0% | ||
| Q2 25 | 4.0% | 22.9% | ||
| Q1 25 | 8.0% | 24.6% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | 20.5% | ||
| Q2 24 | -1.7% | 19.6% | ||
| Q1 24 | 13.2% | 22.3% |
| Q4 25 | $1.14 | $2.05 | ||
| Q3 25 | $1.13 | $1.87 | ||
| Q2 25 | $0.36 | $1.68 | ||
| Q1 25 | $0.69 | $1.57 | ||
| Q4 24 | $-0.45 | $1.29 | ||
| Q3 24 | $-1.27 | $1.15 | ||
| Q2 24 | $-0.14 | $1.00 | ||
| Q1 24 | $0.82 | $1.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $106.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $942.7M |
| Total Assets | $1.4B | $3.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $106.9M | ||
| Q3 25 | $262.6M | $111.7M | ||
| Q2 25 | $217.8M | $81.3M | ||
| Q1 25 | $149.8M | $119.3M | ||
| Q4 24 | $144.9M | $80.4M | ||
| Q3 24 | $145.0M | $86.5M | ||
| Q2 24 | $240.1M | $47.8M | ||
| Q1 24 | $228.6M | $61.4M |
| Q4 25 | $540.7M | $942.7M | ||
| Q3 25 | $505.8M | $878.1M | ||
| Q2 25 | $436.8M | $847.2M | ||
| Q1 25 | $418.6M | $790.4M | ||
| Q4 24 | $403.7M | $729.0M | ||
| Q3 24 | $405.9M | $703.3M | ||
| Q2 24 | $455.8M | $532.6M | ||
| Q1 24 | $452.0M | $501.7M |
| Q4 25 | $1.4B | $3.1B | ||
| Q3 25 | $1.4B | $2.9B | ||
| Q2 25 | $1.3B | $2.8B | ||
| Q1 25 | $1.3B | $2.4B | ||
| Q4 24 | $1.3B | $2.3B | ||
| Q3 24 | $1.3B | $2.3B | ||
| Q2 24 | $920.8M | $2.0B | ||
| Q1 24 | $914.5M | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $409.1M |
| Free Cash FlowOCF − Capex | $29.1M | $409.0M |
| FCF MarginFCF / Revenue | 11.8% | 161.4% |
| Capex IntensityCapex / Revenue | 0.5% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $700.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $409.1M | ||
| Q3 25 | $44.1M | $83.6M | ||
| Q2 25 | $75.8M | $120.9M | ||
| Q1 25 | $35.0M | $87.2M | ||
| Q4 24 | $15.9M | $261.2M | ||
| Q3 24 | $12.5M | $100.3M | ||
| Q2 24 | $17.4M | $55.1M | ||
| Q1 24 | $18.3M | $33.1M |
| Q4 25 | $29.1M | $409.0M | ||
| Q3 25 | $38.0M | $83.6M | ||
| Q2 25 | $71.8M | $120.8M | ||
| Q1 25 | $32.5M | $87.1M | ||
| Q4 24 | $13.5M | $260.9M | ||
| Q3 24 | $7.7M | $100.1M | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | — |
| Q4 25 | 11.8% | 161.4% | ||
| Q3 25 | 16.7% | 34.2% | ||
| Q2 25 | 34.0% | 59.4% | ||
| Q1 25 | 16.5% | 49.9% | ||
| Q4 24 | 7.1% | 167.5% | ||
| Q3 24 | 5.2% | 67.4% | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | — |
| Q4 25 | 0.5% | 0.1% | ||
| Q3 25 | 2.7% | 0.0% | ||
| Q2 25 | 1.9% | 0.0% | ||
| Q1 25 | 1.3% | 0.0% | ||
| Q4 24 | 1.3% | 0.2% | ||
| Q3 24 | 3.2% | 0.1% | ||
| Q2 24 | 3.2% | 0.0% | ||
| Q1 24 | 3.3% | 0.0% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 1.63× | ||
| Q2 25 | 8.87× | 2.60× | ||
| Q1 25 | 2.23× | 2.03× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.29× | ||
| Q2 24 | — | 2.14× | ||
| Q1 24 | 1.00× | 1.26× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PLMR
Segment breakdown not available.
